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SUMMARY 
 
  
IV 
 
Early detection of mother-to-child transfer of Human 
Immunodeficiency Virus (HIV-1) is of the utmost importance for 
monitoring the success of intervention strategies, as well as for 
optimal treatment of HIV-positive children.  Serology can only be 
used confidently after 18 months, as remaining antibodies from the 
mother may give false positive results.  This leaves only molecular 
methods for early detection of the virus; unfortunately, the 
technology is still too expensive for general use. 
 
The aim of this project was to develop and validate a cost-effective, 
fast, early detection method for HIV infection in infants.  PCR was 
chosen as the developmental method, a technique that amplifies 
proviral sequences of HIV DNA, detecting HIV infection in 
peripheral blood mononuclear cells (PBMC) from infants of 
seropositive women during neonatal (age less than 28 days) and 
post-neonatal periods. 
 
A method based on the commercial Roche HIV-1 DNA assay was 
chosen for implementation on the Roche LightCycler instrument.  
The published primer set was used to detect both HIV-1 DNA and 
an internal control.  The target DNA for use as internal control was 
constructed from the plasmid pBR322 so that an AT-rich part of the 
plasmid was flanked by the HIV-1 primer-binding sites. The 
resulting amplicon was cloned into a vector and multiplied in E. coli.  
Amplification of the plasmid by PCR in the Roche LightCycler in the 
presence of SYBR Green created an amplicon having a Tm 
different (81 ± 1°C ) from that of the HIV-1 amplicon (84 ± 1°C) so 
that post-amplification melting can be used to differentiate between 
HIV-1 and internal control. 
 
  
V 
After construction of the internal control, the reaction conditions 
were optimised so that the internal control would amplify strongly 
only in the absence of HIV-1 target DNA.  Then 50 previously 
tested patient samples were analysed using the assay developed 
here.  Only half of the known positive samples came up positive in 
the assay, indicating that it is not sensitive enough for diagnostic 
use in its current form.  Various ways of improving the sensitivity 
are suggested for further development of the assay as described 
here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPSOMMING 
 
  
  
VI 
Vroeë opsporing van moeder-na-kind-oordrag van Menslike 
Immuunge-brekvirus (MIV-1) is belangrik vir die monitering van 
intervensieprogramme asook vir optimale behandeling van MIV-1-
positiewe kinders.  Serologiese diagnose kan eers ná 18 maande 
vertrou word, aangesien die kind tot op daardie stadium nog 
moederlike antiliggaampies in die bloedstroom kan hê.  Dit laat 
slegs molekulêre metodes oor vir vroeë diagnose, maar ongelukkig 
is die tegnologie nog steeds te duur vir algemene gebruik. 
 
Die doel van die projek was die ontwikkeling en validasie van ’n 
koste-effektiewe en vinnige metode vir die vroeë diagnose van 
moeder-na-kind-oordrag van MIV-1.  Polimerase-kettingreaksie- 
(PKR) amplifikasie van provirale MIV-1-DNS in perifere witselkerne 
is die voorkeurmetode van diagnose in neonate (<28 dae) en post-
neonate.   
 
Die algemeen gebruikte kommersiële kwalitatiewe MIV-1-DNS-
metode van Roche is as basis gebruik vir die ontwikkeling van die 
metode wat hier beskryf word.  Die gepubliseerde inleierstel soos 
deur Roche gebruik, is gebruik om beide MIV-1-DNS en ’n interne 
kontrole te teiken.  As interne kontrole is ’n deel van die plasmied 
pBR322 gekies sodat dit ’n laer AT-inhoud as die MIV-1-teiken het.  
Deur middel van amplifikasie met hibried-inleiers is ’n DNS-
molekuul geskep wat die interne kontrole intern het, maar aan 
weerskante bindingsgebiede het vir die MIV-1 inleiers.  Die nuwe 
konstruk is in ’n vektor gekloon en in E. coli vermeerder.  
Amplifikasie van hierdie teiken in die Roche LightCycler in die 
teenwoordigheid van SYBR Green het ’n amplikon opgelewer met 
’n smeltpunt van 81 ± 1°C , wat onderskeibaar is van dié van MIV-
1-DNS (84 ± 1°C). 
 
  
VII 
Ná konstruksie van die interne kontrole is die reaksiekondisies 
geoptimiseer sodat dit slegs sterk amplifiseer in die afwesigheid 
van MIV-1-DNS.  Hierna is 50 monsters wat voorheen getoets is, 
getoets volgens die metode hierbo beskryf.  Slegs die helfte van die 
bekende positiewe monsters het positief opgekom, wat beteken dat 
die metode in sy huidige vorm nie sensitief genoeg is vir 
diagnostiese gebruik nie.  Verskeie voorstelle vir verbetering van 
die sensitiwiteit van die metode word aan die hand gedoen. 
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CHAPTER 1 
________________________________________________ 
INTRODUCTION 
 
In Africa, especially Eastern and Southern Africa, which are most severely 
affected by the HIV/AIDS pandemic, the transmission of HIV from mother to 
child (MTCT) during pregnancy, delivery, and breastfeeding is the most 
common route for human immunodeficiency virus (HIV) infection in children 
(Newell, 1998).  The estimated risk of infection is 5-10% during pregnancy, 
10-20% during labour, and 10-20% during breastfeeding (De Cock et al., 
2000; Harms et al., 2005).  About 20% of the babies who are infected 
through mother-to-child transmission of HIV contract the virus through 
breastfeeding (De Cock et al., 2000).  The baby might be at greater risk from 
breastfeeding if its mother was infected with HIV late in her pregnancy or in 
the months following birth, because of the higher virus count during the 
seroconversion phase of infection.  Women are also more infective when 
they show symptoms of acquired immunodeficiency syndrome (AIDS) (De 
Cock et al., 2000).  What increases the risk even more is the fact that 
between 80% and 90% of women in rural and remote areas in Africa 
breastfeed their babies for two years or longer.  Some African studies have 
shown that breastfeeding increases the risk of infection by between 5% and 
20% (De Cock et al., 2000; Van Dyk, 2001).  Factors that may also affect 
mother-to-child transmission of HIV during breastfeeding are a vitamin A 
deficiency in the mother or child, breast diseases such as mastitis, cracked 
nipples, and diseases such as thrush and gastroenteritis in the infant (Van 
Dyk, 2001). 
 
1.1 Passive immunity 
 
During the first few months of life, the infant begins to acquire protection 
against specific pathogens.  This type of immunity is known as acquired 
immunity and allows the child to mount a specific immune response towards 
 2 
each pathogen the child encounters as it progresses through those first, 
vulnerable months and years (Adler, 1993). During pregnancy, antibodies 
from the mother pass to the child in the uterus. However, these antibodies 
are short-lived, and by the end of three months, the child must begin to 
acquire its own immunity.  For the first three months of its life, the child is 
protected by the natural, passive immunity conferred to it by its mother 
(Adler, 1993). 
 
1.2 Diagnosis of HIV infection in infants 
 
The early diagnosis of HIV infection in infants born to mothers who are HIV-
infected has been challenging, in that passive transfer of maternal antibodies 
to the child leads to detectable antibodies in uninfected children for up to 15 
months of age/after birth.  Polymerase chain reaction (PCR) has changed 
the approach and now allows diagnosis by 14 to 30 days of life in most 
infants (Young et al., 1998).  Demonstration of virus by PCR of HIV 
deoxyribonucleic acid (DNA) from peripheral blood mononuclear cells 
(PBMC), reverse transcription polymerase chain reaction (RT-PCR) of 
ribonucleic acid (RNA) from plasma, or detection of virus by PBMC co-
culture in peripheral blood from the infant (not cord blood), is presumptive 
evidence of infection.  A positive test must be confirmed with a separate 
sample as soon as possible.  Two positive assays drawn at two separate 
time points are considered diagnostic of infection. 
 
Detection of virus within a few days is considered evidence of in utero 
infection, occurring for 30-45% of infected infants (Bryson et al., 1993).  In a 
meta-analysis of data from 271 infected infants, HIV DNA PCR was only 
moderately sensitive within 48 hours of birth (38%; 90% confidence interval 
[CI], 29-46%).  There was little change in the first week of life, but by day 14, 
the sensitivity was 93% (90% CI 76-97%) (Dunn et al.,1995).  The increase 
in detection reflects the ability to detect infected children in the peripartum 
period. The usage of zidovudine monotherapy during the first 4 to 6 weeks of 
life does not seem to interfere with diagnosis (Connor et al., 1994). 
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1.3 Management of HIV-exposed infants 
 
A reasonable diagnostic strategy is to perform PCR testing within 48 hours of 
birth, then at 14 to 30 days of life.  However, many experts prefer to test 
between 14 days and 1 month to allow earlier diagnosis, and there is no 
evidence that this reduces sensitivity.  Infants with repeatedly negative viral 
tests should be followed for evidence of loss of HIV antibodies.  All children 
born to HIV-infected mothers should be treated using the ACTG 076 
protocol, with 2mg/kg being administered every 6 hours beginning within a 
few hours of birth and continuing for 4-6 weeks after being given zidovudine.  
In women for whom intrapartum nevirapine is being considered because of 
inadequate prenatal treatment or failure to suppress maternal viraemia, it is 
reasonable to also include a dose for the infants within 48 hours of birth.  
This provides nevirapine concentration in the infants that remains for more 
than 7 days (Mirochnick et al., 1998). 
 
There is no consensus on the management of children born to mothers with 
documented resistance to zidovudine.  Increased rates of transmission have 
been documented when the mother has a circulating resistant virus (Walles 
et al., 2000), and it is logical to use drugs that would be predicted to be 
active against the maternal strain.  Pneumocystis prophylaxis is 
recommended for all HIV-infected infants, as well as those of unknown 
status, beginning at 4-6 weeks of age.  For children who are documented to 
be uninfected and have normal CD4 cell counts, prophylaxis can be stopped 
by 4 to 6 months of age (Walles et al., 2000). 
 
1.4 Viral load 
 
The viral load is the amount of virus found in the bloodstream.  The 
quantitative HIV-1 RNA testing (HIV-1 viral load) detects and quantifies the 
HIV-1 RNA in plasma.  The viral load is given as a value representing RNA 
copies per millilitre, as well as a log value, e.g. 100 = 2 log, 1000 = 3 log, 
10000 = 4 log etc.  The log value provides an easier number to work with and 
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better indicates significant changes in viral load (Powderly et al., 1999; 
Spencer, 2005; National Department of Health, 2004). 
 
As seen in the graph (Figure 1.1), viral load is highest during the acute 
phase of primary infection (before antibodies are developed) and at end 
stage AIDS.  Viral load tests indicate the effectiveness (or lack of effects) of 
treatment and the expected rate of disease progression; the higher the viral 
load, the faster the progression (The viral load count, 2009).   
 
 
Figure 1.1. The viral load count 
(Adapted from The viral load count, 2009) 
 
1.5 The need for Antiretroviral Therapy 
 
In spite of the advances in the antiretroviral drug therapy, HIV/AIDS remains 
a force to be reckoned with, even in developed countries.  Antiretroviral 
therapy is associated with improved clinical well-being in children.  
Monotheraphy with zidovudine, didanosine, or stavudine demonstrated 
improved immunologic parameters, neurodevelopmental status and growth 
(Butler et al., 1991; McKinney et al., 1991; Kline et al., 1995).  Combination 
therapy, with zidovudine and didanosine, zidovudine and lamivudine, or 
didanosine and stavudine, has subsequently been shown to be superior to 
monotherapy (Englund et al., 1997; McKinney et al., 1998; Kline et al., 1999). 
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The usage of protease inhibitor-containing triple combinations, either in 
treatment-experienced or treatment-naive children, confers significantly 
greater immunologic and virologic benefits than two-drug therapy (Nachman 
et al., 2000; Van Rossum et al., 2000; Wiznia et al., 2000).  Triple 
combination therapy is associated with a significant survival benefit in 
children, as in adults, as demonstrated in prospective cohort studies (De 
Martino et al., 2000).  The Italian HIV National AIDS registry study estimated 
that there was a reduction of almost 70% in the relative hazard of death 
associated with triple therapy compared to no antiretroviral therapy (De 
Martino et al., 2000).  
 
1.6 Immune reconstitution and when to start therapy in infants 
 
The pattern of immune reconstitution in infants differs from that of adults 
(Borkowsky et al., 2000).  It is likely that this is related to greater thymic 
activity in infants (Douek et al., 2000; Viganò et al., 2000).  Compared to 
adults, children have an earlier and larger increase in naive CD4 cells and 
larger overall increases in CD4 count.  In small studies, children have shown 
improvement in response to recall antigens and broadening of the T-cell 
receptor repertoire (Viganò et al., 1999). 
 
Early initiation of therapy is associated with several potential problems, 
adherence to complex regimens with unpleasant formulations is difficult, yet 
adherence is the key determination of success (Watson & Farley, 1999; 
Reddington et al., 2000).  It is becoming clear that metabolic complications of 
combination antiretroviral therapy, such as fat accumulation, fat atrophy, 
glucose intolerance, dyslipidemia, and lactic acidosis, affect a significant 
portion of infants, and risk factors and reversibility are poorly understood 
(Babl et al., 1999; Jaquet et al., 2000).  When initiating therapy in infants, 
monitoring protease inhibitor concentrations should be strongly considered if 
available.  For children older than one year, the decision on when to start 
therapy is more complicated.  Antiretroviral therapy in all children, regardless 
of immunologic status or symptoms, should be initiated, or therapy should be 
deferred in children with normal immune status who are at low risk of disease 
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progression. Therapy should be considered when there is evidence of high 
viral load (Babl et al., 1999; Jaquet et al., 2000). 
 
1.7 The aim of the study 
 
The aim of this project was to develop and validate a cost-effective, fast, 
early detection method for HIV infection in infants.  PCR was used as the 
developmental method, a technique that amplifies proviral sequences of HIV 
DNA, detecting HIV infection in peripheral blood mononuclear cells from 
infants of seropositive women during neonatal (age less than 28 days) and 
post-neonatal periods. 
 
1.8 The objectives of the study 
 
The final objective is to develop an alternative assay for testing babies for 
mother-to-child transfer of HIV-1. In order to reach this objective, the 
following has to be adhered to: 
1. Identify a method satisfying the criteria of sensitivity, specificity, ease 
of use and speed. 
2. Obtain the required oligonucleotides and other reagents to design and 
construct an internal control  using the same set of primers as the 
primary target.  This is to control for successful amplification and 
should be positive in the absence of HIV-1 DNA, otherwise it is 
impossible to distinguish between a true negative result and failed 
amplification.  Ideally, an extraction control should be used which 
goes through the whole process together with the primary target, but 
for a proof-of-concept project like this, an amplification control should 
suffice. 
3. Do the same for the assay itself. 
4. Test the full reaction (target and internal control) in order to optimize it. 
5. Test on a number of previously tested samples. It should perform on 
par or better than the current method before it can be implemented. 
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CHAPTER 2 
_____________________________________ 
LITERATURE REVIEW 
 
One of the most important infectious diseases is acquired immune 
deficiency syndrome (AIDS).  This disease is caused by infections 
with human immunodeficiency virus (HIV) and is characterized by 
profound immunosuppression with associated opportunistic 
infections and malignant tumours, wasting, and central nervous 
system (CNS) degeneration.  The virus is transferred through blood 
and body fluids.  Blood, semen, vaginal secretions, breast milk, and 
to a small extent, saliva of an infected individual, contain free virus 
or cells containing virus.  Thus, HIV can be transmitted through 
sexual contact, sharing of needles, transfusion of blood or blood 
products, placental transfer, passage through the birth canal, and 
breast feeding (Benjamin et al., 2000). 
 
The UNAIDS Secretariat and the World Health Organisation 
estimated that at the end of 2007, approximately 33 million people 
were living with HIV infections globally (Figure 2.1).  It is also 
estimated that the annual number of new HIV infections declined 
from 3 million in 2001 to 2,7 million in 2007 and that 2 million 
people died due to HIV-related causes during 2007, compared with 
an estimated 1,7 million people in 2001.  
 
Southern Africa continues to bear a disproportionate share of the 
global burden of HIV: 35% of HIV infections and 38% of AIDS 
deaths in 2007 occurred in that sub region. Altogether, sub-
Saharan Africa is home to 67% of all people living with HIV. Half of 
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all people living with HIV worldwide are women, and nearly 60% of 
HIV infections are in Sub-Saharan Africa (Figure 2.2).  
 
      
 
Young people aged 15-24 years account for an estimated 45% of 
new HIV infections worldwide. An estimated 370 000 children 
younger than 15 became infected with HIV in 2007. Globally, the 
number of children younger than 15 living with HIV increased from 
1,6 million in 2001 to 2 million in 2007 (Figure 2.2). Almost 90% of 
children younger than 15 years live in Sub-Saharan Africa and 
acquired the virus during pregnancy, birth, or breastfeeding.  
 9 
  
 
Figure 2.2 Children living with HIV globally, 1990-2007 
(Adapted from UNAIDS, 2008) 
 
A small fraction of HIV infections in children are caused by 
contaminated injections, the transfusion of infected blood or blood 
products, sexual abuse, sexual intercourse, or scarification (Hauri 
et al., 2004; Kiwanuka et al., 2004; Schmid et al., 2004). 
 
In Figure 2.3, new HIV infections in children appear to have 
peaked in 2000-2002, due to the stabilization of the prevalence of 
HIV among women overall, and to the increasing coverage of 
programmes for preventing mother-to-child transmission of HIV.  
Since 2003-2007 the HIV prevalence in infected children has slowly 
been decreasing.  In 2005 alone, 700 000 children acquired HIV 
infection through mother–to-child transmission before, during, and 
after delivery.  HIV infections in childbearing women is as high as 
57%, and vertically acquired HIV infection is now reversing positive 
downwards trend in infant and child mortality previously seen in 
Sub-Sahara Africa (Giaquinto et al., 2006). 
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Figure 2.3 New HIV infections among children, 1990-2007 
(Adapted from UNAIDS, 2008) 
 
 
 
Figure 2.4 Child deaths due to AIDS, 1990-2007 
(Adapted from UNAIDS, 2008) 
 
As Figure 2.4 illustrates, the total number of AIDS death in children 
peaked in 2003 and has been decreasing since. This decline 
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mainly reflects the drop in new infections seen earlier (visible in 
Figure 2.3), as well as increased access to antiretroviral treatment. 
 
2.1 The HIV epidemic in South Africa 
 
In Sub-Saharan Africa, there are an estimate of 1,9 million people 
who are  infected with HIV, bringing to 22 million the number of 
people living with HIV. Two thirds (67%) of the global total of 33 
million people living with HIV, live in this region, and three quarters 
(75%) (Figure 2.5) of all AIDS deaths occurred there in 2007 
(UNAIDS, 2008). 
 
                  
 
Figure 2.5 Estimated number of adults living with HIV. 
 Global HIV epidemic, 1990-2007; and HIV epidemic in Sub-Saharan Africa, 1990-2007.  
(Adapted from UNAIDS, 2008) 
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 Since 2003, surveys have confirmed that the trend has changed, 
so that the level of HIV prevalence is now growing slowly.  The 
most encouraging finding concerns teenage girls (15-24 years of 
age), among whom prevalence has been declining since 1999 
(Avert, 2008).  Based on the sample of 33 488 women attending 
1 415 antenatal clinics across all nine provinces, the South African 
Department study estimates that 28% of pregnant women were 
living with HIV in 2007.  The provinces that recorded the highest 
HIV rates were KwaZulu-Natal, Free State, and Gauteng (Table 
2.1) The Northern Cape and Western Cape recorded the lowest 
prevalence (Avert, 2008).  HIV data from antenatal clinics in South 
Africa suggests that the country’s epidemic might be decreasing in 
some provinces, but there is no evidence yet of major changes of 
HIV-related behaviour.  The estimated 5,7 million South Africans 
living with HIV in 2007 makes this the largest HIV epidemic in the 
world (UNAIDS, 2008). 
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Table 2.1 Estimated HIV prevalence among antenatal clinic attendees, 
according to province (Avert, 2008). 
 
Province 2000 
Prev.% 
2001 
Prev.% 
2002 
Prev.% 
2003 
Prev.% 
2004 
Prev.% 
2005 
Prev. % 
2006 
Prev. % 
KwaZulu- 
Natal  
 
Gauteng 
 
Free State 
 
Mpumalanga 
 
North West 
 
Eastern Cape 
 
Limpopo 
 
Northern Cape 
 
Western Cape 
 
National 
 
36,2 
 
29,4 
 
27,9 
 
29,7 
 
22,9 
 
20,2 
 
13,2 
 
11,2 
 
8,7 
 
24,5 
 
33,5 
 
29,8 
 
30,1 
 
29,2 
 
25,2 
 
21,7 
 
14,5 
 
15,9 
 
86 
 
24,8 
 
36,5 
 
31,6 
 
28,8 
 
28,6 
 
26,2 
 
23,6 
 
15,6 
 
151 
 
12,4 
 
26,5 
 
37,5 
 
29,6 
 
30,1 
 
32,6 
 
29,9 
 
27,1 
 
17,5 
 
16,7 
 
13,1 
 
27,9 
 
40,7 
 
33,1 
 
29,5 
 
30,8 
 
26,7 
 
28,0 
 
19,3 
 
17,6 
 
15,4 
 
29,5 
 
39,1 
 
32,4 
 
30,3 
 
34,8 
 
31,8 
 
29,5 
 
21,5 
 
18,5 
 
15,7 
 
30,2 
 
39,1 
 
30,8 
 
31,1 
 
32,1 
 
29,0 
 
29,0 
 
20,7 
 
15,6 
 
15,2 
 
29,1 
 
Prev. = Prevalence 
 
2.2 Transmission of HIV from mother to child 
 
The most complex and difficult challenge in the field of maternal 
and child health is the need to protect children from this virus, for 
which there is no vaccine (Holmes & Kwarteng, 2001).  Mother-to-
child transmission occurs during pregnancy, at the time of labour or 
delivery and afterwards through breastfeeding.  The estimated rate 
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of mother-to-child transmission of HIV ranges from 15-30% in the 
non-breastfeeding population and from 25-45% in breastfed 
children, which means that over half of all children born to HIV-
infected women are not infected (De Cock et al., 2000).  
 
Even when antiretroviral prophylaxis successfully reduces the risk 
of mother-to-child transmission late in pregnancy and during 
delivery, postnatal transmission through breastfeeding remains an 
important risk (De Cock et al., 2000).  Mother-to-child transmission 
is responsible for more than 90% of these infections.  Mother-to-
child transmission is the most dominant mode of HIV infection 
among young children worldwide, whereby there are at least 1 700 
new infections each day and more than one paediatric infection 
every minute (Peter, 2006).   
 
HIV transmission from mother to infant can occur antepartum (in 
utero), intrapartum (during labour or delivery), or postpartum 
(through breastfeeding). It is suggested that in the absence of 
breastfeeding, 30% of infant infections occur during pregnancy, 
70% occur during labour and delivery, and during breastfeeding. 
Where formula feeding is not available, breastfeeding contributes 
substantially to the risk of transmission, accounting for 
approximately one third of cases (Giaquinto et al., 2006). 
 
Babies of HIV positive mothers have a higher risk of low weight, 
prematurity, stillbirth, and perinatal mortality.  Clinical features 
which are common of HIV infection in children are recurrent and 
persistent diarrhoea, oral thrush, generalized lymphadenopathy, 
itchy rashes, chronic cough, developmental delay, neurological 
problems, parotitis, recurrent bacterial infections, and especially 
pneumonia.  Children developing signs of infections in their first 
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year have a poor prognosis and most die within 3 years (Holmes & 
Kwarteng, 2001).  Some develop symptoms for the first time in their 
second or third year and continue to grow well, although they may 
have frequent minor illnesses (Holmes & Kwarteng, 2001).   
 
HIV transmission occurs early through breast milk, although some 
risks continue throughout the period of breastfeeding (Nduati et al., 
2000).  Most babies, who are born to HIV-infected mothers and are 
breastfed, do not become infected with HIV, and these infants 
probably benefit from the general and HIV-specific antibodies in 
breast milk (Tozzi et al., 1990).  Some African studies have shown 
that breastfeeding increases the risk of infection by between 15% 
and 30% (Van Dyk, 2001).  Factors that may also affect mother-to-
child transmission of HIV during breastfeeding are a vitamin A 
deficiency in the mother or child, breast diseases such as mastitis, 
cracked nipples, and diseases such as thrush and gastroenteritis in 
the infant (Van Dyk, 2001). 
 
2.3 The specific immune response 
 
During the first few months of life, the infant begins to acquire 
protection against specific pathogens.  This type of immunity is 
known as acquired immunity, and it allows the child to mount a 
specific immune response towards each pathogen he or she 
encounters as it progresses through those first few vulnerable 
months and years.  During pregnancy, antibodies from the mother 
pass to the child in the uterus.  However, these, antibodies are 
short-lived, and by the end of three months, the child must begin to 
acquire its own immunity.  For the first three months of its life, the 
child is protected by the natural, passive immunity conferred to it by 
its mother (Adler, 1993).  Because of the maternal HIV antibodies 
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crossing the placenta, it is difficult to diagnose HIV infection in 
infants up to 18 months of age without access to advanced tests 
such as PCR (Holmes & Kwarteng, 2001).   
 
2.4 Types and Subtypes of HIV 
 
There are two types of human AIDS viruses, HIV-1 and HIV-2, 
which are distinguished according to their genome organization and 
phylogenetic relationships with other primate lentiviruses (Figure 
2.6).  HIV-1 has three distinct virus groups: M (majority), O 
(outliers) and N (non-M/non-O).  The majority of infected individuals 
in the world have HIV-1 group M, which comprises of ten different 
subtypes, designated clades A through K on the basis of 
phylogenetic analysis of genomic or sub-genomic proviral 
sequences (Machuca et al., 2001; Choisy et al., 2004; Glass, 
2006).  The O and N virus groups are found in Africa, with a low 
prevalence (Simon et al., 1998; Liitsola, 2000).  Similarly, HIV-2 
comprises of six subtypes, A through F.  Comparison of HIV 
subtypes to simian immunodeficiency virus (SIV) provides clues as 
to the origins of HIV, as well as providing a valuable animal model.  
Five major lineages of primate lentiviruses have been fully 
sequenced, helping to place the origins of HIV in Central Western 
Africa (Hahn et al., 2000; Choisy et al., 2004). 
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Figure 2.6 Phylogenetic relationships among primate 
lentiviruses 
 The tree is a composite of several analyses based on viral gag, pol and full-
length genome alignment 
(Adapted from Alaeus, 2000) 
 
The HIV viruses are members of the lentivirus family of retroviruses 
(Clavel et al., 1986; Keren & Warren, 1992; Marlink et al., 1994; 
Witten & Perelson, 2004).  Retroviruses are RNA viruses that 
replicate through DNA intermediates using the viral enzyme reverse 
transcriptase (Price & Perry, 1994).  HIV-1 and HIV-2 contain a few 
different proteins.  The clinically available enzyme linked 
immunosorbent assays (ELISA’s) for HIV-1 will cross-react with 
from 59 to 91 percent of HIV-2 antibody-positive sera.  HIV-2 
appears to be transmitted in the same manner as HIV-1.  Although 
clinical experience with HIV-2 is limited, HIV-2, like HIV-1, is known 
to produce decreased CD4 cell count, lymphadenopathy, 
immunosuppression, and AIDS.  Some researchers have 
suggested that HIV-2 may have a longer incubation period than 
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HIV-1 infection and that HIV-2 infected patients may have a 
somewhat longer survival rate (Sigal & Ron, 1994). 
 
2.5 Differences between subtypes 
 
It is essential to understand the biological and geographical 
differences between subtypes.  HIV-1 group M, subtypes A & D, 
are predominant in Sub-Saharan Africa, while subtype C is 
predominant in South Africa, India, and Nepal (Relucio & Holodniy, 
2002).  The populations of Japan, Australia, the Caribbean, Europe, 
and the Americas are mostly affected by subtype B (McCutchan, 
1999; Michael et al., 1999).  Subtype E occurs in the Central 
African Republic, as well as Thailand and other countries of 
Southeast Asia, while subtype F (Brazil & Romania), subtypes G & 
H (Russia and Central Africa) and subtype I (Cyprus) clades are of 
a very low prevalence (Kahn, 2003).  Primarily group O HIV-1 
strains have been detected in Western African countries like 
Cameroon.  The first group N HIV-1 strain was found in Cameroon 
in 1998, since viruses from this particular group are exceedingly 
rare (Relucio & Holodniy, 2002).  Different subtypes vary in their 
effect on their host.  Variance in disease progression is caused by 
the biological differences between strains and subtypes and the 
genetic difference between hosts.  T-cell counts act as a measure 
of virus progression and are therefore a common way to estimate 
the virulence of subtypes (Kuiken, 1999). 
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2.6 Virology of HIV-1 
 
HIV-1 is a single-stranded diploid RNA virus, 100-200µm in 
diameter (Adler et al., 1993).  The RNA component is 9749 
nucleotides long (Ratner et al., 1985).  Two major viral-envelope 
proteins, gp120 and gp41, form spikes (Roux & Taylor, 2007).  The 
HIV-1 lipid bilayers are made up of various host proteins, including 
class I and class II histocompatibility antigens, which are obtained 
during virion budding.  The proteins p24, p17, p6, and p7 are the 
four nucleocapsid proteins contained in the care of HIV-1, each of 
which is cleaved from 53kD gag precursor by the HIV-1 protease.  
The main component of the inner layer of the nucleocapsid is 
formed by the phosphorylated p24 capsid (Figure 2.7).  The 
myristoylated p17 protein is associated with the inner surface of the 
lipid bi-layer and probably stabilizes the exterior and interior 
components of the virion. 
 
The p7 matrix binds directly to the genomic RNA through a zinc-
finger structural motif and, together with p9, forms the nucleoid 
core.  This retroviral core contains two copies of the single stranded 
HIV-1 genomic RNA, which is associated with the various pre-
formed viral enzymes, including two reverse transcriptase 
components, integrase and protease (Coffin, 1995; Parren et al., 
1999; Turner & Summers, 1999). 
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  CHAPTER 3 
______________________________________________________ 
MATERIALS AND METHODS 
 
3.1 MATERIALS 
 
3.1.1 Patient samples 
 
The ethical committee of CUT (ETOVS 32/03) cleared the project and fifty 
HIV positive DNA samples (from EDTA blood) were used to develop and 
evaluate the new PCR method.  In March 2004, the samples were tested by 
PathCare Laboratories in Cape Town using the Roche Amplicor HIV-1 DNA 
kit. The samples were supplied without any way of linking them to specific 
patients, therefore it was not deemed necessary to obtain informed consent.  
 
3.1.2. Nucleic Acids (Plasmids and Primers) 
 
Plasmid pBR322 purchased from Promega was taken from the frozen stocks 
of the Department of Haematology and Cell Biology. Plasmid pGEM-T Easy 
was purchased from Promega. The primers summurized in Table 3.1 were 
designed using the AlleleID (Biosearch Technologies) program, employing 
settings to search for an amplicon with a low Tm on pBR322.  The binding 
sites of the primers are 4038-4062 for PS1 and 4127-4147 for PS2.  Primers 
PS1 and PS2 were tailed with the HIV-1 primers SKCC1B and SK145 so that 
the amplicon may be amplified using the latter set of primers.   
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Figure 3.1 pBR322 plasmid (4361 kb) 
(Adapted from Molecular cloning, vectors pBR322 DNA, 2009) 
 
 
 
Table 3.1 Primers used for PCR methods  
  
Primers Number of bases Sequence 
PS1 55 bases AGTGGGGGGACATCAAGCAGCCATGCAAATCCCAAC 
TGATCTTCAGCATGTTTTA 
PS2 49 bases TACTAGTAGTTCCTGCTATGTCACTTCCATTCAACATTT 
CCGTGTCGCC 
SKCC1B 28 bases TACTAGTAGTTCCTGCTATGTCACTTCC 
SK145 30 bases AGTGGGGGGACATCAAGCAGCCATGCAAAT 
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3.1.3  Chemicals and media 
 
All chemicals were of analytical grade and were purchased from the following 
companies: Sigma ALDRICH, (Steinheim, Germany), Promega (Madison, 
USA) and Roche Diagnostics (Indianapolis, USA).  Reagents for PCR were 
purchased from Roche.  Microbiological media was supplied by Difco 
(Franklin Lakes, New Jersey, USA), and Merck (Darmstadt, Germany). 
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3.2 METHODS 
 
3.2.1 Extraction of genomic DNA 
 
The Promega Wizard Genomic Purification DNA kit was used to extract DNA 
from 300µl EDTA blood (see 3.1.1).  The following procedure was followed; 
900µl of cell lysis solution was pipetted into a sterile1,5ml microcentrifuge 
tube.  The tube of blood was gently inverted until thoroughly mixed.  Then 
300µl of blood was transferred to the tube containing the cell lysis solution.  
The mixture of the blood cells was incubated for 10 minutes at room 
temperature and centrifuged at 14 000xg in a microcentrifuge for 1 minute.  
As much supernatant as possible was removed and discarded without 
disturbing the visible white pellets.  If some of the red blood cells and red cell 
debris were visible along with the white blood cells the procedure was 
repeated. 
 
The tube was vigorously vortexed until the white blood cells resuspended 
(10-15 seconds).  Then 300µl of nuclei lysis solution was added to the tube 
containing the resuspended cells.  The solution was pipetted 5-6 times to 
lyse the white blood cells until the solution became very viscous.  If the 
clumps were visible after mixing, the solution was incubated at 37°C until the 
clumps were disrupted.  If the clumps were still visible after 1 hour, an 
additional 100µl of nuclei lysis solution was added and the incubation was 
repeated.  Then 100µl of protein precipitation solution was added to the 
nuclear lysate and vortexed vigorously for 20 seconds.  Small protein clumps 
were occasionally visible after vortexing.  The solution was centrifuged at 14 
000xg for 3 minutes at room temperature.  A dark brown protein pellet was 
visible and the supernatant was transferred to a clean microcentrifuge tube 
containing 300µl of room temperature isopropanol. 
 
The solution was gently mixed until the white thread-like strands of DNA 
were visible as a small white pellet.  The supernatant was removed and 300 
µl of 70% ethanol at room temperature was added to the DNA.  The tube 
was gently inverted several times to wash the DNA pellet and the sides of 
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microcentrifuge tube, and then centrifuged for 1 minute at 14 000xg at room 
temperature.  The ethanol was carefully aspirated using a drawn Pasteur 
pipette.  Because the DNA pellet was very loose, care was taken to avoid 
aspiration of the pellet.  The tube was inverted on to a clean absorbent paper 
and the pellet dried for 15 minutes.  The 100µl of DNA rehydrating solution 
(10mM Tris-HCl/1mM EDTA, pH 7,4) was added to the tube and the DNA 
was dehydrated by incubating at 65°C for 1 hour.  Then the solution was 
gently mixed by tapping the tube.  The DNA was rehydrated by incubating 
the solution overnight at room temperature and storing it at 4°C. 
 
3.2.2  Polymerase chain reaction 
 
Amplification reactions were carried out in a total volume of 50µl which 
contained the following: primers (100-200nM), 200μM of dNTPs, 5µl of 
reaction buffer (10X), 5 units of Taq polymerase, 1.5-3mM MgCl2 and a 
variable amount of pBR322 DNA as template.  The PCR cycling was as 
follows: denaturation step at 95ºC for 2 minutes, 30 cycles at 95ºC for 10 
seconds, 55-60ºC for 10 seconds and 72ºC for 10 seconds, with one cycle at 
72ºC for 5 minutes.  
 
3.2.3  Agarose gel electrophoresis 
 
Two percent gels were prepared by adding an appropriate amount of 
agarose to 50ml TBE.  This was heated in a microwave oven until all the 
agarose was dissolved.  After being cooled down, 2,5µl ethidium bromide (10 
mg/ml) was added.  The gel was poured in the gel plate and left for 30 
minutes to solidify.  Then 5µl DNA was mixed with 5µl of loading buffer 
(0,25% bromophenol blue in 40% sucrose solution) and loaded in separate 
slots and electrophoresed at 80 volts for 1 hour in 1 x TBE buffer.  Then the 
bands were visualized on a UV transilluminator.  A 100 bp ladder (Promega) 
was used as size standard. 
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3.2.4  Purification of DNA from agarose gels 
To purify the DNA a GenElute Agarose Spin Column kit (Sigma) was used.  
The column was placed into a collection tube and pre-washed by adding 1x 
TE (10mM Tris, pH8,0, 1mM EDTA).  The spin column was capped and 
centrifuged at 14 000xg for 10 seconds.  Then the GenElute Agarose Spin 
Column was transferred to a fresh collection tube.  The bands of interest 
from the agarose gel of the amplified PCR product were cut and loaded into 
the pre-washed column.  The GenElute Agarose Spin Column was 
centrifuged at 14 000xg for 10 minutes.  The purified DNA in the collection 
tube was centrifuged for 15 minutes at maximum speed.  The supernatant 
was then discarded and the pellet was washed with 20µl of 70% ethanol 
(room temperature).  Subsequently, the DNA pellet was dried for 5 minutes 
and resuspended in 20µl TE buffer (10mM Tris, pH8,0, 1mM EDTA). 
 
3.2.5 Preparation of LB medium 
 
Table 3.2 Two mixtures of LB medium for plates (1) or liquid (2). 
 MIXTURE 1 MIXTURE 2 
H2O 200ml 200ml 
TRYPTONE 2,0g 2,0g 
YEAST EXTRACT 1,0g 1,0g 
NaCl 2,0g 2,0g 
AGAR 3,0g 0,0g 
 
 
The mixtures were autoclaved for 20 minutes at 121ºC.  Two hundred 
microlitres of 50% ethanol was mixed in 25mg/ml Ampicillin to mixture 1 
(Table 3.2), after which it was poured into the plates and left in the fume 
hood to solidify.  
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3.2.6  Cloning of PCR products 
 
The pGEM-T Easy Vector System kit (Promega) was used for cloning of the 
PCR amplicon resulting from primers PS1 and PS2 and pBR322 as 
template. 
 
Table 3.3 Cloning the fragment of amplified PCR product. 
TUBES                   FRAGMENTS CONTROL INSERT NEGATIVE CONTROL 
2X Rapid ligation 
buffer  
5µl 5µl 5µl 
pGEM-T Easy 
(50ng/µl) 
1µl 1µl 1µl 
PCR fragments 3µl - - 
Control insert DNA 
(4ng/µl) 
- 2µl - 
T4 DNA ligase (3u/µl) 1µl 1µl 1µl 
H20 - 1µl 3µl 
 
Three Eppendorf tubes were prepared from the above reagents.  They were 
incubated at room temperature for 1 hour. 
 
3.2.7  Electroporation of ligated DNA  
 
Three tubes of electrocompetent cells were thawed and 2,5µl of ligated 
mixture was added to each tube.  Each was mixed well and kept on ice for 1 
minute.  The cell suspension was loaded into 2mm cuvettes, which were 
chilled beforehand on ice.  Two thousand five hundred volts was selected as 
the output voltage of the electroporator (Bio-Rad). The pulse was triggered 
immediately.  After the pulse, 500µl of liquid LB medium was added.  The 
cells were transferred into Eppendorf tubes and incubated at 37ºC for 1 hour 
before being centrifuged at 4 000xg for 2 minutes.  Three hundred and fifty µl 
of the supernatant of each mixture was removed and each pellet was 
carefully mixed.  The cells were plated on selective media containing 
Ampicillin, and incubated overnight at 37°C. 
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3.2.8 Identification of insert-containing colonies  
 
Twenty colonies were picked randomly from the plate using toothpicks and 
stabbed onto a new plate in a grid pattern.  After overnight incubation at 
37°C, a small fraction of each colony was picked up and used to inoculate 1 
ml aliquots of LB + Amp medium.  After overnight culture at 37°C, 10μl was 
taken from each culture at room temperature and then boiled for 5 minutes 
and centrifuged at 4 000xg for 5 minutes.  Five microlitres of each 
supernatant was used in a PCR reaction, using primers SK145 and 
SKCC1B.  Products were analysed on a 2% agarose gel and colonies 
showing a product of the correct size were identified as containing inserts. 
 
3.2.9 Isolation of plasmid DNA from E. coli 
 
The remaining liquid culture of an insert-positive colony from 3.2.8 was used 
to inoculate 1 litre of LB + Amp, which was incubated overnight with shaking 
at 37°C.  The GenElute Plasmid Maxiprep Kit from Sigma was used as 
follows: The overnight mixture was divided evenly into the conical tubes, then 
centrifuged at 8 000xg for 10 minutes before the media supernatant was 
discarded.  The pellet was washed with 40ml of H2O and centrifuged at 
8 000xg for 10 minutes, after which the supernatant was discarded.  The 
bacterial pellet was resuspended with 6ml of resuspension solution (50mM 
Tris-HCl (pH7,5); 10mM EDTA) that was mixed with RNase A (100µg/ml).  
The pellet was vortexed until all the cells were completely resuspended as a 
homogenous suspension.  The resuspended cells were lysed by adding 6ml 
of lysis solution (0,2M NaOH and 1% SDS).  Then the cells were gently 
inverted 8-10 times until the mixture became clear and viscous.  The cells 
were incubated at room temperature for 2 minutes. 
 
The cell debris was precipitated by adding 8ml of neutralization/binding 
buffer (1,32M potassium acetate, pH4,8).  The tube was gently inverted 4-6 
times and centrifuged at 14 000xg for 10 minutes.  The cell debris, proteins, 
lipids, SDS, and chromosomal DNA fell out as a cloudy, viscous precipitate.  
The supernatant was re-centrifuged if the floating supernatant contained a 
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large amount of floating particles after centrifugation.  A GenElute Maxiprep 
Binding Column was inserted into a 50ml collection tube and the cleared 
lysate was transferred to the column, then centrifuged at 4 000xg for 2 
minutes.  The flow-through liquid was discarded.  Eight millilitres of optional 
wash solution (80mM potassium acetate, 8,3mM Tris-HCl, pH7.5, 40µM 
EDTA) was added to the GenElute Maxiprep Binding Column, centrifuged at 
4 000xg for 5 minutes, after which the flow-through liquid was discarded.  
Fifteen millilitres of diluted wash solution (80mM potassium acetate, 8,3mM 
Tris-HCl, pH7.5, 40µM EDTA) was added to the GenElute Maxiprep Binding 
Column and centrifuged at 4 000xg for 5 minutes.  The flow-through liquid 
was discarded and centrifuged again at 14 000xg for 2 minutes without 
additional wash solution to remove excess ethanol.  The GenElute Maxiprep 
Binding Column was transferred to a fresh 50ml collection tube.  One millilitre 
of elution solution (10mM Tris-HCl, 1mM EDTA pH8.0) was added to the 
column and centrifuged at 4 000xg for 5 minutes.  The results were observed 
by mixing 2µl of the solution with 5µl of loading buffer and the total volume 
was run on a 2% agarose gel using 1kb marker. 
   
3.2.10  Ethanol precipitation 
 
Two and a half volumes absolute ethanol and 1/10 volume of 3M NaAc were 
routinely used and the mixture was put on ice for 30 minutes.  The solution 
was spun at 14 000xg for 15 minutes and the supernatant was carefully 
removed.  Then 50µl of room temperature 70% of Ethanol (EtOH) was added 
and spun for 5 minutes; the supernatant was very carefully removed.  The 
pellet was dried in the Speed vaccum for 5 minutes and then resuspended in 
50-200µl TE (10mM Tris, pH8.0, 1mM EDTA). 
 
3.2.11 Digestion of DNA with restriction enzymes 
 
Two hundred microlitres of insert-containing plasmid DNA from 3.2.10, 25µl 
of SuRE/Cut Buffer H, 5µl EcoR1 (Roche) and 20µl of water was added into 
an Eppendorf tube and incubated at 37ºC for 2 hours.  The results were 
 
 
44 
observed by mixing 2µl of the solution with 5µl of loading buffer and the total 
volume was run on a 2% agarose gel using 1kb marker. 
 
3.2.12 DNA concentration determination 
 
Five microlitres of DNA was added to 95μl of TE and the dilution was added 
to a 100μl cuvette.  A Pharmacia Genequant spectrophotometer was used at 
260 and 280nm to determine the concentration and purity of the DNA. 
 
3.2.13  LightCycler experiments 
 
The Roche Lightcycler was used as platform for the new assay in 
combination with the FastStart DNA Master PLUS SYBR Green reaction mix.  
Reactions of 20μl were composed of 4μl mastermix, 2μl Taq polymerase 
enzyme, 5μl of primer mix (final concentration 200 μM each) 5 microlitre 
DNA and 4μl water.  The following profile was used throughout:  10 minutes 
at 95°C followed by 45 cycles consisting of 10 seconds at 95°C, 10 seconds 
at 60°C and 15 seconds at 72°C.  Fluorescence measurements in channel 
F1 were taken at the end of each elongation step at 72°C.  The amplicons 
were then denatured at 95°C for 10 seconds, annealed at 60°C for 1 minute 
and heated at 0.1°C per second to 95°C to determine their melting 
temperatures.  During the melting step, fluorescence data was captured 
continuously in channel F1.  Every experiment contained a no-template 
control without DNA to look for contamination and also to get a background 
profile. 
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CHAPTER 4 
RESULTS AND DISCUSSION 
 
4.1 Construction of an internal control using pBR322 
 
A competitive internal control, using the same primers as the Roche 
Amplicor HIV-1 DNA assay, but amplifying a different amplicon, was 
designed.  The reasoning behind it was to amplify a short length (109bp, 
167bp HIV SK primers included) of pBR322, specially selected for having 
a high (Adenine + Thymine) A+T content so that it would have a low 
melting point.  The amplicon generated from integrated HIV by the two SK 
primers is 157 bp in size and was calculated to have a Tm of 85°C, while 
the pBR322-derived fragment should have a Tm of 75-78°C depending on 
which program is used for the calculation.  Hybrid primers were designed 
to prime on pBR322, besides having priming sites for the two Roche 
primers, SK145 and SKCC1B.  The result of amplifying pBR322 DNA 
using primers PS1 and PS2 is shown in Figure 4.1.   
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Figure 4.1 Electrophoretic analysis of pBR322 amplification 
 Lane M is the molecular marker (Promega 100 bp ladder), 
lane 1 indicates the amplified fragment. 
 
A band of the correct size (between 100 and 200bp) was visible in lane 1, 
while the no template control in lane 2 was empty.   This PCR product was 
subsequently cloned into the Promega pGEM-T Easy vector which has 
overhanging thymine (Ts) to enable accommodation of the amplicon 
having adenine (A) overhangs.  The ligated mixture was used to transform 
E. coli by electroporation, and a number of colonies were picked up for 
analysis from Ampicillin plates.  These were stabbed onto a new Ampicillin 
plate and used to inoculate small cultures which served as templates for 
direct amplification of inserts from the plasmids.  The resulting PCR 
products were separated on an agarose gel (Figure 4.2). 
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Figure 4.2 Agarose gel electrophoresis of amplicons 
From crude extracts of plasmid-containing colonies 1, 6, 7 and 9 
were chosen for further analysis. 
 
Plasmid DNA was purified from the rest of the cultures of the colonies 
chosen for further analysis.  Since the insertion site of the PCR fragments 
in pGEM-T Easy is flanked closely by EcoR1 restriction sites, the plasmids 
were digested by EcoR1 and analyzed by agarose gel electrophoresis 
(result not shown).  One of the clones showing the correctly-sized 
fragment was selected and inoculated into 100ml medium for isolating a 
large amount of plasmid DNA.  In turn, this DNA was digested with EcoR1 
and analyzed by gel electrophoresis (Figure 4.3). 
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Figure 4.3 Agarose gel electrophoresis of EcoR1 digested plasmid DNA 
Lane 1 supercoiled plasmid; lane 2, digested plasmid and lane 3,  
the original PCR fragment. 
 
The EcoR1-digested plasmid produced an insert of between 100 and 
200bp, while the original fragment was somewhat smaller.  The size 
difference can be due to a slight size difference (about 10bp due to the 
EcoR1 sites), as well as the effect of salt from the restriction buffer.  The 
migration of small DNA fragments is easily perturbed by minor differences 
in salt and/or size. 
 
The plasmid containing the insert was now deemed ready for testing as an 
internal control.  It was thought better to have the insert removed by 
EcoR1 digestion to change it from supercoiled plasmid to linear DNA, an 
easier target for PCR. 
 
4.2 Testing the internal control 
 
The concentration of the digested plasmid was determined by UV 
spectrophotometry, from which the copy number was calculated.  This 
was deemed necessary to establish the amplification characteristics of the 
construct.  A dilution series was made and analyzed on the LightCycler, 
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the results of which are shown in Figure 4.4.  From this it is clear that the 
lower limit of detection is in the region of 1 000 target copies/ml, which 
works out at 20 copies per reaction.  
 
Figure 4.4 Determination of the detection sensitivity of the internal 
control reaction.   
A 10-fold dilution series ranging from 1 million to10 copies/ml were run in triplicate. 
 
Table 4.1.  Crossing points (Cp) of the dilution series 
Copy number 106 105 104 103 102 101 
 
Cp 
 
19,7 ± 
0,8 
 
23,1 ± 
0,9 
 
27,0 ± 
0,6 
 
31 ± 
1.3 
 
35* 
 
 
>45 
*Only 2 of the 3 lines came up 
 
The standard curve constructed from the dilution series had a slope of -3,6 
and an efficiency of 92%. It can be seen in Table 4.1 that the crossing 
point differences between successive 10-fold dilutions are close to 4, 
where it should ideally be 3,33.  As the same primers are used for the 
internal control and HIV-1 DNA detection and since the amplicon sizes are 
similar, these figures can be applied to the primary reaction as well.  This 
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assumption implies that the lowest copy number detectable by this method 
is 20 copies of integrated HIV-1 DNA per reaction, which does not bode 
well for its intended application. 
   
Strand separation, annealing, and slow denaturation while continuously 
following the fluorescence resulted in the set of melting curves shown in 
Figure 4.5.  The melting point of amplicon (Tm) turned out to be 81 ±1˚C, 
somewhat higher than expected.  It should be noted that the formulas 
used for predicting the Tm of DNA molecules assume “ideal” conditions, 
where the salt concentration, including magnesium, is exactly known.  
Unfortunately, the exact compositions of commercial Taq polymerase 
buffers are not given and may contain components different from the 
classical buffers, which may influence Tm values. 
 
Figure 4.5 Melting curves of the amplicons generated in Figure 4.4. 
 
Apart from the peak at 81˚C, another is seen at 64˚C, even in the no 
template controls (the lines at the bottom). Surprisingly, in the 
amplification plot (Figure 4.4), no amplification is seen in the no template 
controls.  The peak is most probably caused by primer dimers or other 
primer-primer interactions, and they are not seen in the amplification plots 
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since the data capture is done at 72˚C, where the structures are melted 
completely.  These secondary reactions are most probably responsible for 
the relatively poor efficiency of the reaction, since a sizable portion of the 
primers are sequestered in this primer-primer interaction.  In an effort to 
reduce the effect of this side-reaction, the annealing temperature was 
varied between 55 and 65˚C, and the primer concentration between 100 
and 200M using the 1000 copies/ml samples as target (results not 
shown).  The optimal conditions turned out to be annealing temperature 
(Ta) of 60 degrees and primer concentration of 200M as it gave a good 
trade-off between primer dimer formation and sensitivity.  These 
conditions were used for the rest of the work. 
 
4.3 Addition of positive control 
 
An artificial positive control was created by reamplification of remaining 
material from a Cobas Amplicor-tested positive sample.  No attempt was 
made to determine its concentration by spectrophotometry, as too much 
handling of this amplicon may cause contamination.   A dilution series was 
made to find a suitably diluted sample to use as realistic positive control.  
It was then added to reactions containing internal control to see the effect 
of having both targets in the same reaction. The amount of internal control 
was chosen as 500 copies/ml, halfway between the lowest value where all 
3 came up (1 000 copies/ml) and the next value where none came up (100 
copies/ml).  It can be seen from Figure 4.6 that a high copy number 
sample (blue line) had a low crossing point, but that all the others, 
including the no template control, crossed the threshold at cycle 33, since 
they all contain the same amount of internal control.  Also, note that the 
internal control crossed the threshold at the expected range, between 
cycle 31 and 35 (Table 4.1), showing that it is not shifted by competition 
with the positive control. 
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The melting curves of the amplicons are shown in Figure 4.7.  The Tm of 
the positive control, predicted to be 85˚C, turned out to be 84˚C, not too 
far from the expected value.  That brings it close to the Tm of the internal 
control, but far enough to distinguish them reliably.  The high 
concentration (blue line) made a single peak at 84˚C, while an 
intermediate concentration (green line) showed a double peak. 
 
 
 
Figure 4.6 Amplification of samples containing internal control and 
various amounts of positive control. 
 
All the others had only the single internal control peak at 80-81˚C.  This 
means that the internal control is strong enough to come up in all samples, 
but weak enough to be suppressed by the presence of a high copy 
number of primary target.  Unfortunately, the copy number of the artificial 
positive control could not be established accurately without running the 
risk of contaminating the laboratory with the same amplicon that is the 
target for the rest of the study. 
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Figure 4.7 Melting curves of the samples in figure 4.6. 
 
4.4. Evaluation using patient samples 
 
The final test of the method was to retest a number of samples that were 
tested before in the laboratories of PathCare in Cape Town.  DNA was 
isolated from 50 patient samples and 5l of each were tested in the assay 
described here, containing 500 copies/ml of internal control.  An example 
of the results is shown in Figure 4.9.  Six of the 30 samples tested in that 
run were found positive by the Roche Amplicor HIV-1 DNA method, but 
only 3 came up with the in-house assay, the first line to cross the 
threshold being the positive control.  It is known that the proviral load can 
be very low in adult patients, while babies may have a spectrum of loads, 
from very low to very high.  An ideal method should be sensitive enough to 
identify the lowest level possible while retaining a large dynamic range so 
as not to be saturated by high proviral loads.  The melting curves of the 
samples in Figure 4.8 are shown in Figure 4.9. 
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Figure 4.8 Amplification curves of 30 patients’ samples. 
 
 
 
Figure 4.9 Melting curves of the samples shown in figure 4.8. 
 
No information was known about the patients in this group as the samples 
have been anonymised to protect patient identity, which made it 
impossible to stratify patients into sex or age groups.  It is possible that the 
samples that were positive in the in-house assay were from babies and 
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the others from adults.  In this case, the method could potentially be useful 
for early detection of mother-to-child transfer of HIV-1, although it would 
take a brave person to use a method that is not ultrasensitive for this 
purpose.  The unfortunate conclusion from this evaluation of real-life 
samples is that the assay described in this thesis will miss roughly half of 
the positives identified by the Roche method in general use. 
 
The lack of sensitivity can be blamed on a number of factors: 
Firstly, while the Roche method uses 50l of extract, the in-house method 
uses only 5, giving it a built-in tenfold disadvantage.  This becomes 
especially important in cases where very low levels of target are expected.  
PCR can potentially detect a single copy of a DNA target and the chances 
are better for a target molecule to be present in a larger volume.  
Unfortunately, it is impractical to scale up the in-house assay as the 
maximum practical volume that can be used in the LightCycler capillary is 
25l.  Scaling up will also increase the cost as most of the running cost of 
real-time PCR is in the reagents used. 
 
Secondly, the assay can probably be split into 2 capillaries per patient, 
one for HIV-1 DNA and one for the internal control.  This will eliminate 
competition between the two reactions and could help push down the limit 
of detection.  On the other hand, this will double the cost of the assay as 
well as increase the complexity, two things that we wanted to avoid. 
 
Thirdly, SYBR Green assays rely purely on detection of the amplicon by 
amplification and subsequent identification by melting of the amplicon.  
The Roche method relies on detection of the amplicon by an amplicon-
specific capture probe followed by ELISA detection of the bound amplicon.  
The assay thus relies on two amplification steps, namely, amplification of 
the HIV-1 DNA target, followed by signal amplification in the ELISA step.  
 56 
Together, these steps give the assay incredible sensitivity, but also a very 
low saturation level, meaning that it cannot be used quantitatively.   
 
The assay described in this thesis is thus not suitable for diagnostic use 
and another approach should used to get better sensitivity.  Most in-house 
assays described in the literature use some form of probe detection, either 
Taqman, molecular beacons, or scorpions.  This seems to be the most 
promising avenue to explore for an alternative assay.  Meanwhile, the 
Roche assay with its batching requirement and labour intensity will remain 
the mainstay of HIV-1 molecular diagnostics. 
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